WO2011139255A3 - Compositions pharmaceutiques comprenant du céfétamet - Google Patents

Compositions pharmaceutiques comprenant du céfétamet Download PDF

Info

Publication number
WO2011139255A3
WO2011139255A3 PCT/TR2011/000133 TR2011000133W WO2011139255A3 WO 2011139255 A3 WO2011139255 A3 WO 2011139255A3 TR 2011000133 W TR2011000133 W TR 2011000133W WO 2011139255 A3 WO2011139255 A3 WO 2011139255A3
Authority
WO
WIPO (PCT)
Prior art keywords
cefetamet
pharmaceutical compositions
preparation
pharmaceutically acceptable
relates
Prior art date
Application number
PCT/TR2011/000133
Other languages
English (en)
Other versions
WO2011139255A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11724475A priority Critical patent/EP2566450A2/fr
Publication of WO2011139255A2 publication Critical patent/WO2011139255A2/fr
Publication of WO2011139255A3 publication Critical patent/WO2011139255A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Abstract

L'invention concerne des compositions pharmaceutiques comprenant du céfétamet, un dérivé pharmaceutiquement acceptable de cette substance ainsi que leur procédé de préparation.
PCT/TR2011/000133 2010-05-04 2011-05-02 Compositions pharmaceutiques comprenant du céfétamet WO2011139255A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11724475A EP2566450A2 (fr) 2010-05-04 2011-05-02 Compositions pharmaceutiques comprenant du céfétamet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201003545 2010-05-04
TR2010/03545 2010-05-04

Publications (2)

Publication Number Publication Date
WO2011139255A2 WO2011139255A2 (fr) 2011-11-10
WO2011139255A3 true WO2011139255A3 (fr) 2012-05-03

Family

ID=44201076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000133 WO2011139255A2 (fr) 2010-05-04 2011-05-02 Compositions pharmaceutiques comprenant du céfétamet

Country Status (2)

Country Link
EP (1) EP2566450A2 (fr)
WO (1) WO2011139255A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109202A2 (fr) * 2012-01-18 2013-07-25 Mahmut Bilgic Composés pharmaceutiques comprenant du céfétamet
CN104876947B (zh) * 2015-05-06 2017-09-29 山东罗欣药业集团股份有限公司 盐酸头孢他美酯水合物晶体及其分散片

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1600313A (zh) * 2003-09-28 2005-03-30 东北制药总厂 盐酸头孢他美酯分散片及其制备方法
CN101612138A (zh) * 2009-07-16 2009-12-30 浙江亚太药业股份有限公司 盐酸头孢他美酯胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396681A (en) 1981-06-10 1983-08-02 Essex Chemical Corporation Process for coating one pot moisture curable coating composition onto non-porous substrate and article
CN1650868A (zh) 2004-12-02 2005-08-10 四川川投医药生物技术有限责任公司 一种治疗肺部感染性疾病的复方药物制剂及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1600313A (zh) * 2003-09-28 2005-03-30 东北制药总厂 盐酸头孢他美酯分散片及其制备方法
CN101612138A (zh) * 2009-07-16 2009-12-30 浙江亚太药业股份有限公司 盐酸头孢他美酯胶囊及其制备方法

Also Published As

Publication number Publication date
EP2566450A2 (fr) 2013-03-13
WO2011139255A2 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
EP2535339A4 (fr) Polymorphes du dasatinib, leurs procédés de préparation et leurs compositions pharmaceutiques
WO2011098582A3 (fr) Nouvelles formes de chlorhydrate d'ivabradine
WO2012174487A3 (fr) Inhibiteurs à bromodomaine et leurs utilisations
WO2012151512A3 (fr) Inhibiteurs de bromodomaines et leurs utilisations
WO2012075383A3 (fr) Inhibiteurs de bromodomaines et leurs utilisations
WO2011130615A3 (fr) Synthèse de lacosamide
WO2011017502A3 (fr) Formulations comprenant du linaclotide
WO2012174158A3 (fr) Administration de benzodiazépine
WO2011157721A3 (fr) Composition pharmaceutique contenant de l'ivabradine
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
WO2013055684A8 (fr) Citramide de rasagiline
PL2562172T3 (pl) Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania
WO2012070062A3 (fr) Nouveau polymorphe de chlorhydrate de nilotinib
WO2012101653A3 (fr) Compositions pharmaceutiques de mémantine à libération modifiée
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
WO2014068586A3 (fr) Compositions orales solides de tolvaptan
WO2012137227A3 (fr) Formes solides de composés antirétroviraux, procédé de préparation correspondant et composition pharmaceutique de ces composés
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
WO2013128379A3 (fr) Formes polymorphes cristallines de linagliptine
WO2010006904A3 (fr) Nouvelles formes cristallines du rabéprazole sodique
EP2785335B8 (fr) Procédés et compositions pharmaceutiques pour le traitement de la maladie de darier
WO2011045774A3 (fr) Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11724475

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011724475

Country of ref document: EP